Menu Search
Equities

Eagle Pharmaceuticals Inc

1E6:DEU

Eagle Pharmaceuticals Inc

Actions
  • Price (EUR)4.16
  • Today's Change0.22 / 5.58%
  • Shares traded0.00
  • 1 Year change-83.75%
  • Beta--
Data delayed at least 15 minutes, as of May 07 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial capabilities. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The Company also has a research and development facility in Cambridge, Massachusetts. The Company has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.

  • Revenue in USD (TTM)257.55m
  • Net income in USD11.95m
  • Incorporated2007
  • Employees134.00
  • Location
    Eagle Pharmaceuticals Inc50 Tice Boulevard, Suite 315WOODCLIFF LAKE 07677United StatesUSA
  • Phone+1 (201) 326-5300
  • Fax+1 (302) 655-5049
  • Websitehttps://www.eagleus.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.